Diabetes & Endocrinologytype 2 diabetesketoacidosis
Ketoacidosis Risk with SGLT2 Inhibitors in Type 2 Diabetes: Insights from a Scandinavian Cohort Study
By MedXY|Sep 5, 2026
A large Scandinavian study reveals that ketoacidosis risk during SGLT2 inhibitor therapy in type 2 diabetes varies by patient factors and persists beyond early treatment, highlighting the need for ongoing risk assessment and management stra